Cargando…

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones.OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most res...

Descripción completa

Detalles Bibliográficos
Autores principales: Barani, Mahmood, Mukhtar, Mahwash, Rahdar, Abbas, Sargazi, Saman, Pandey, Sadanand, Kang, Misook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924594/
https://www.ncbi.nlm.nih.gov/pubmed/33672770
http://dx.doi.org/10.3390/bios11020055
_version_ 1783659121496555520
author Barani, Mahmood
Mukhtar, Mahwash
Rahdar, Abbas
Sargazi, Saman
Pandey, Sadanand
Kang, Misook
author_facet Barani, Mahmood
Mukhtar, Mahwash
Rahdar, Abbas
Sargazi, Saman
Pandey, Sadanand
Kang, Misook
author_sort Barani, Mahmood
collection PubMed
description Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones.OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients’ overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it.
format Online
Article
Text
id pubmed-7924594
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79245942021-03-03 Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma Barani, Mahmood Mukhtar, Mahwash Rahdar, Abbas Sargazi, Saman Pandey, Sadanand Kang, Misook Biosensors (Basel) Review Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones.OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients’ overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it. MDPI 2021-02-20 /pmc/articles/PMC7924594/ /pubmed/33672770 http://dx.doi.org/10.3390/bios11020055 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barani, Mahmood
Mukhtar, Mahwash
Rahdar, Abbas
Sargazi, Saman
Pandey, Sadanand
Kang, Misook
Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title_full Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title_fullStr Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title_full_unstemmed Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title_short Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma
title_sort recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924594/
https://www.ncbi.nlm.nih.gov/pubmed/33672770
http://dx.doi.org/10.3390/bios11020055
work_keys_str_mv AT baranimahmood recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma
AT mukhtarmahwash recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma
AT rahdarabbas recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma
AT sargazisaman recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma
AT pandeysadanand recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma
AT kangmisook recentadvancesinnanotechnologybaseddiagnosisandtreatmentsofhumanosteosarcoma